Ask about this productRelated genes to: ABCG2 Blocking Peptide
- Gene:
- ABCG2 NIH gene
- Name:
- ATP binding cassette subfamily G member 2 (Junior blood group)
- Previous symbol:
- -
- Synonyms:
- EST157481, MXR, BCRP, ABCP, CD338
- Chromosome:
- 4q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1999-10-26
- Date modifiied:
- 2019-04-23
Related products to: ABCG2 Blocking Peptide
Related articles to: ABCG2 Blocking Peptide
- Glioblastoma multiforme (GBM) is a lethal and fast-growing brain cancer that is difficult to treat with standard medical interventions. GBM tumors often overexpress cyclin-dependent kinase 9, in complex with cyclin T1, and thus, it represents a promising target for therapeutic intervention. In this study, we employed a structure-based virtual screening approach for a curated library of 6,059 bis-pyridyl compounds from PubChem to identify potential CDK9/T1 inhibitors. Subsequent ADP-Glo assay led to the identification of GNE-3511 as a potent CDK9/T1 inhibitor with an IC of 0.064 μM. GNE-3511 also inhibited CDK7/cyclin H with an IC of 0.12 μM. In U-87 MG and T98G glioblastoma cells, GNE-3511 exhibited cytotoxicity with a GI of 3.4 and 5.0 μM, inducing G2/M phase cell cycle arrest and promoting early apoptosis. Treatment with GNE-3511 significantly reduced the expression of the anti-apoptotic markers BCL-2, SURVIVIN and drug resistance markers ( and ) in a dose-dependent manner, and downregulated glioma stem cell population/markers (, CD90, or CD133 and ) and sphere formation abilities. Oral administration of GNE-3511 at 20 mg/kg (twice daily) demonstrated significant anti-tumor efficacy and improved survival in both U-87 MG and T98G xenograft/orthotopic mouse models. Collectively, these findings highlight GNE-3511 as a promising lead candidate for the development of GBM therapeutics. - Source: PubMed
Publication date: 2026/05/14
Pr Nithya SreeSomarowthu TejaswiS JeyasankariKuncha MadhusudhanaAndugulapati Sai BalajiBharate Sandip B - To evaluate the relationship between low-functioning single-nucleotide variants of rs1045642, rs1128503, and rs2032582 of the gene and rs2231142 of the gene and clinical and laboratory parameters in patients with schizophrenia taking clozapine. - Source: PubMed
Kidyaeva A VTulendinov E RAgaev A MNasyrova R F - Hyperuricemia (HUA) is a prevalent metabolic disorder requiring safe, effective interventions. (LR), a Chinese functional tea approved as a general food by the National Health Commission of the People's Republic of China, was studied for its anti-HUA and renoprotective effects in potassium oxonate and hypoxanthine-induced HUA mice. Results showed that LR significantly reduced serum uric acid and improved renal function in a dose-responsive manner without organ toxicity. Western blot analysis indicated that LR bidirectionally regulated uric acid metabolism by downregulating the expressions of XOD, URAT1, GLUT9, and OAT4 and upregulating ABCG2, OAT1 and OAT3 expressions. Furthermore, transcriptomics combined with RT-qPCR and H&E staining revealed that LR ameliorated renal inflammation by suppressing the TNF/NF-κB pathway. Using spectrum-effect relationship analysis, 20 active compounds were identified, with ligupurpuroside A and verbascoside showing strong XOD inhibitory activity. LR shows promise as a safe, effective functional food for HUA management. - Source: PubMed
Publication date: 2026/05/14
Tian Xiao-LongZheng ZuoWang QianRan Jun-YanZhang Ying-CaiZhou Dong-MeiLang XinJiang LiYan Xue-LongFang XiangLiao Shang-Gao - Hyperuricemia (HUA), a metabolic disorder resulting from disrupted uric acid (UA) homeostasis, is the principal etiological factor for gout. This study investigated the therapeutic potential of gut microbiota modulation in HUA using antibiotic-treated mouse models with butyrate intervention. Selective antibiotic screening identified the -type strain (Dn) as an effective intervention for HUA. Dn treatment significantly reduced UA production, improved renal function markers, and decreased oxidative stress. Dn enriches and while suppressing the pathobiont , thereby enhancing the production of acetate, propionate, and butyrate. Molecular analyses demonstrated that Dn downregulated the expression of URAT1 while upregulating ABCG2, thereby promoting UA excretion. Histopathological evaluation confirmed that Dn restored the glomerular atrophy, tubular dilation, and collagen deposition induced by HUA. These findings suggest that Dn is a promising multitarget therapeutic agent for HUA and provides a scientific foundation for the development of novel microbiome-based strategies against HUA. - Source: PubMed
Publication date: 2026/05/13
Cheng XinyuLei YifanZhang ShuyangChen LipingWang Yongzhong - This study aimed to optimize the ultrasonic-assisted extraction of polyphenols from and to evaluate their anti-hyperuricemic effects. Polyphenols from medicinal plants have attracted increasing attention due to their potential roles in regulating uric acid metabolism. In this study, single-factor experiments combined with Box-Behnken response surface methodology were employed to optimize extraction conditions, and an entropy weighting method was applied to integrate total polyphenols and Archidendrin I into a comprehensive evaluation index. The bioactivity of the obtained extract was further assessed through in vitro assays and a hyperuricemic mouse model. The optimal extraction conditions were determined to be 50% ethanol, a liquid-to-material ratio of 30, and 31 min of sonication, yielding 175 mg GAE/g DW of total polyphenols and 80.34 mg/g DW of Archidendrin I. The extract exhibited significant xanthine oxidase inhibitory activity, reduced serum uric acid levels, regulated urate transporters (URAT1, GLUT9, and ABCG2), and alleviated renal and hepatic injury in hyperuricemic mice. These findings indicate that the optimized process enables efficient extraction of polyphenols from , and the resulting extract exerts beneficial regulatory effects on uric acid metabolism, highlighting its potential as a natural agent for hyperuricemia management. - Source: PubMed
Publication date: 2026/04/27
Yan DannaHong ZiyanZhao ZhiminYang WenzheYang Depo